Cargando…
MyD88 signalling is critical in the development of pancreatic cancer cachexia
BACKGROUND: Up to 80% of pancreatic cancer patients suffer from cachexia, a devastating condition that exacerbates underlying disease, reduces quality of life, and increases treatment complications and mortality. Tumour‐induced inflammation is linked to this multifactorial wasting syndrome, but mech...
Autores principales: | Zhu, Xinxia, Burfeind, Kevin G., Michaelis, Katherine A., Braun, Theodore P., Olson, Brennan, Pelz, Katherine R., Morgan, Terry K., Marks, Daniel L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463469/ https://www.ncbi.nlm.nih.gov/pubmed/30666818 http://dx.doi.org/10.1002/jcsm.12377 |
Ejemplares similares
-
Establishment and characterization of a novel murine model of pancreatic cancer cachexia
por: Michaelis, Katherine A., et al.
Publicado: (2017) -
Microglia in the hypothalamus respond to tumor‐derived factors and are protective against cachexia during pancreatic cancer
por: Burfeind, Kevin G., et al.
Publicado: (2020) -
Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia
por: Olson, Brennan, et al.
Publicado: (2021) -
Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer
por: Burfeind, Kevin G, et al.
Publicado: (2020) -
MyD88 deficiency aggravates the severity of acute pancreatitis by promoting MyD88-independent TRIF pathway-mediated necrosis
por: Yang, Du-Jiang, et al.
Publicado: (2022)